EP1112373A2 - Mesure enzymatique de l'acide mycophenolique - Google Patents

Mesure enzymatique de l'acide mycophenolique

Info

Publication number
EP1112373A2
EP1112373A2 EP00935908A EP00935908A EP1112373A2 EP 1112373 A2 EP1112373 A2 EP 1112373A2 EP 00935908 A EP00935908 A EP 00935908A EP 00935908 A EP00935908 A EP 00935908A EP 1112373 A2 EP1112373 A2 EP 1112373A2
Authority
EP
European Patent Office
Prior art keywords
mycophenolic acid
impdh
nadh
nad
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00935908A
Other languages
German (de)
English (en)
Other versions
EP1112373B1 (fr
Inventor
Allan R. Dorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics Operations Inc
Original Assignee
Roche Diagnostics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Corp filed Critical Roche Diagnostics Corp
Publication of EP1112373A2 publication Critical patent/EP1112373A2/fr
Application granted granted Critical
Publication of EP1112373B1 publication Critical patent/EP1112373B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Definitions

  • the present invention is based upon the uncompetitive inhibition of the enzyme inosine-5'-monophosphate dehydrogenase (IMPDH) by mycophenolic acid (MPA).
  • IMPDH inosine-5'-monophosphate dehydrogenase
  • MPA mycophenolic acid
  • the rate of formation of NADH (reduced nicotinamide adenine dinucleotide) can be measured by monitoring the change in absorption at a wavelength of 340 nm, i.e., the characteristic absorption region of NADH, and this change in absorption can then be correlated to the MPA concentration.
  • the IMPDH enzyme preferred for use is a recombinant IMPDH-II enzyme from human T lymphocytes.
  • Figure 1 shows the structures of MPA and the glucuronide metabolites of MPA.
  • the determination of MPA according to the present invention may be conducted by a rate-assay method wherein change in absorbance of NADH per unit time is measured or by an end-point method wherein the reaction is quenched after a certain period of time has elapsed.
  • the method can easily be applied to automated analyzers for laboratory or clinical analysis.
  • Other methods for measuring NADH are also contemplated, for example, the reduction of NAD is coupled to the reduction of a tetrazolium salt, 2-/?-nitrophenyl-5-phenyl tetrazolium chloride (INT), with phenazine methosulfate serving as an intermediate electron carrier, as described in Babson, A.L. et al, Clinical Chemistry 19(1):166-169 (1973).
  • the decrease in absorbance rate at 340 nm is inversely proportional to the mycophenolic acid concentration in the sample.
  • Concentrations of MPA are calculated by the instrument by comparing the rate of production of NADH by the unknown sample with the rate of production of NADH by the standards containing known amounts of MPA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP00935908A 1999-06-09 2000-05-11 Mesure enzymatique de l'acide mycophenolique Expired - Lifetime EP1112373B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US328741 1994-10-27
US09/328,741 US6107052A (en) 1999-06-09 1999-06-09 Enzymatic measurement of mycophenolic acid
PCT/US2000/012872 WO2000075363A2 (fr) 1999-06-09 2000-05-11 Mesure enzymatique de l'acide mycophenolique

Publications (2)

Publication Number Publication Date
EP1112373A2 true EP1112373A2 (fr) 2001-07-04
EP1112373B1 EP1112373B1 (fr) 2006-07-19

Family

ID=23282234

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00935908A Expired - Lifetime EP1112373B1 (fr) 1999-06-09 2000-05-11 Mesure enzymatique de l'acide mycophenolique

Country Status (8)

Country Link
US (1) US6107052A (fr)
EP (1) EP1112373B1 (fr)
JP (1) JP3854864B2 (fr)
AT (1) ATE333510T1 (fr)
CA (1) CA2339821C (fr)
DE (1) DE60029413T2 (fr)
ES (1) ES2267541T3 (fr)
WO (1) WO2000075363A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524808B1 (en) * 1999-06-25 2003-02-25 Roche Diagnostics Corporation Enzyme inhibition immunoassay
US6811998B2 (en) * 1999-06-25 2004-11-02 Roche Diagnostics Operations, Inc. Conjugates of uncompetitive inhibitors of inosine monophosphate dehydrogenase
DE60140929D1 (de) * 2000-11-14 2010-02-11 Roche Diagnostics Gmbh Immunoassay für HIV-Protease-Hemstoffe
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
JP2005508671A (ja) * 2001-07-26 2005-04-07 アバンテク バスキュラー コーポレーション 治療に有効な薬剤の送達
WO2005051229A2 (fr) * 2003-11-24 2005-06-09 Avantec Vascular Corporation Dispositifs et procedes d'administration d'agents therapeutiques
US7276362B2 (en) * 2004-01-30 2007-10-02 Roche Diagnostics Operations, Inc. Recombinant histidine-tagged inosine monophosphate dehydrogenase polypeptides
WO2005105768A2 (fr) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processus de préparation d'acide mycophénolique et de dérivés d'ester
DK2032712T3 (da) * 2006-06-29 2010-05-25 Ivax Pharmaceuticals Sro Regulering af syremetabolitproduktion
BRPI0803097A2 (pt) * 2007-04-11 2011-11-08 Teva Gyogyszergyar ... método para redução do nìvel de impurezas na fermentação do ácido micofenólico
CN113396226A (zh) * 2019-01-31 2021-09-14 豪夫迈·罗氏有限公司 氨检测测定中nadph或nadh的稳定化

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US5665583A (en) * 1988-08-12 1997-09-09 Arch Dev Corp Methods and materials relating to IMPDH and GMP production
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994012184A1 (fr) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Utilisation d'acide mycophenolique, de mofetile de mycophenolate ou d'un derive de ceux-ci pour inhiber la stenose
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6225073B1 (en) * 1994-07-07 2001-05-01 Dade Behring Marburg Gmbh Immunoassay for mycophenolic acid
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
SK286662B6 (sk) * 1996-04-23 2009-03-05 Vertex Pharmaceuticals Incorporated Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu
US6153398A (en) * 1997-12-24 2000-11-28 The University Of Chicago Method to identify specific inhibitors of IMP dehydrogenase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0075363A2 *

Also Published As

Publication number Publication date
CA2339821C (fr) 2009-01-27
CA2339821A1 (fr) 2000-12-14
JP2003523730A (ja) 2003-08-12
ATE333510T1 (de) 2006-08-15
ES2267541T3 (es) 2007-03-16
DE60029413T2 (de) 2007-02-22
JP3854864B2 (ja) 2006-12-06
EP1112373B1 (fr) 2006-07-19
US6107052A (en) 2000-08-22
WO2000075363A2 (fr) 2000-12-14
WO2000075363A3 (fr) 2001-04-12
DE60029413D1 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
US6107052A (en) Enzymatic measurement of mycophenolic acid
Furusu et al. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis
Walsh et al. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes
Matsumaru et al. Mechanisms for sensitization to TNF‐induced apoptosis by acute glutathione depletion in murine hepatocytes
ES2605247T3 (es) Métodos para la detección de fármacos hidrófobos
ES2323553T3 (es) Determinacion de diaminooxidasa.
Villanueva et al. Reduced folate carrier: tissue distribution and effects of chronic ethanol intake in the micropig
EP1105730B1 (fr) Immunoessai base sur l'inhibition enzymatique
Fabiani et al. Prolongation and improvement of prostasome promotive effect on sperm forward motility
Nakane et al. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1
Derubertis et al. Activation of murine lymphocytes by cyclic guanosine 3′, 5′-monophosphate: Specificity and role in mitogen action
Zeid et al. Cytoprotection by fructose and other ketohexoses during bile salt‐induced apoptosis of hepatocytes
CA2244733A1 (fr) Procede d'inhibition de l'activite d'adenylosuccinate synthetase dans les cellules deficientes en methylthioadenosine phosphorylase
O'Dorisio et al. Human monocyte killing of Staphylococcus aureus: modulation by agonists of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate
US6524808B1 (en) Enzyme inhibition immunoassay
Villagrasa et al. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes
JP3864261B2 (ja) マイコフェノリック酸アッセイのための試薬
Wang et al. Involvement of cyclic AMP generation in the inhibition of respiratory burst by 2-phenyl-4-quinolone (YT-1) in rat neutrophils
Inada et al. Cilostazol, a cyclic AMP phosphodiesterase inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase activity in SH-SY5Y human neuroblastoma cells
Yamamoto et al. Effect of ethanol ingestion on nucleotides and glycolytic intermediates in erythrocytes and purine bases in plasma and urine: acetaldehyde-induced erythrocyte purine degradation
US20080113397A1 (en) Enzymatic Measurement of Imatinib Mesylate
Gong et al. Effect of hypoxia on the pharmacokinetics and metabolism of zaleplon as a probe of CYP3A1/2 activity
TANIMOTO et al. Characterization of aldose reductases Ia and Ib from rabbit lens
WO2010109009A1 (fr) Méthodes de détection et de traitement de maladie due au prion aberrant
Evereklioglu et al. Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behçet's disease: is it a new urinary activity marker?

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20041117

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE DIAGNOSTICS OPERATIONS, INC.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060719

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060719

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060719

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060719

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60029413

Country of ref document: DE

Date of ref document: 20060831

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061019

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061019

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: F. HOFFMANN-LA ROCHE AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061219

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2267541

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060719

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070511

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20190523

Year of fee payment: 20

Ref country code: DE

Payment date: 20190412

Year of fee payment: 20

Ref country code: ES

Payment date: 20190603

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190417

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20190425

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20190425

Year of fee payment: 20

Ref country code: GB

Payment date: 20190430

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60029413

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20200510

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 333510

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20200510

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20201110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20200512